JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
JCR Pharmaceuticals Co., Ltd. has issued a correction to its previously filed Consolidated Financial Results for FY2023, citing partial errors in the ‘Summary’ and ‘Consolidated Financial Statements’. The corrected report maintains the year-on-year growth in net sales, operating profit, ordinary profit, and profit attributable to owners of parent, while adjusting the comprehensive income figures for the year ended March 31, 2024, to 6,475 million yen.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
